BioCryst Pharma Affirms FY2026 Sales Guidance of $635.000M-$660.000M vs $666.201M Est
BioCryst Pharma (NASDAQ: BCRX ) affirms FY2026 sales outlook from $635.000 million-$660.000 million to $635.000 million-$660.000 million vs $666.201 million estimate.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.